Background. Little is known about variation in antibody responses targeting the full spectrum of Epstein-Barr virus (EBV) proteins and how such patterns inform disease risk.
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that infects >90% of individuals worldwide [1] . Primary infection with the virus typically occurs in early childhood [2, 3] , after which EBV establishes lifelong latency in human B cells. During the course of lifelong infection, EBV periodically reactivates in B cells or epithelial cells, expressing a broader set of lytic proteins required for viral replication [4] . This ongoing replication in epithelial cells of the oral cavity contributes to shedding of the virus into saliva, facilitating person-to-person transmission of EBV.
Although established EBV infection is generally asymptomatic, infection manifests as clinical disease in a subset of infected individuals; such diseases include hematopoietic malignancies (eg, Burkitt and Hodgkin lymphomas) and epithelial malignancies (eg, gastric cancer and nasopharyngeal carcinoma [NPC] ) [4] . EBV is etiologically involved in approximately 200 000 cancers worldwide each year [5] . Despite its ubiquity and association with various chronic conditions, there are currently no proven ways to prevent EBV infection from occurring or to predict with sufficient accuracy which infected individuals will develop serious chronic diseases associated with this virus [5, 6] .
One way to monitor patterns of EBV exposure in the general population is to measure levels of circulating anti-EBV antibodies that reflect responses to viral proteins. For example, immunoglobulin G (IgG) antibodies appear within several weeks after primary infection and remain in circulation for many years [7] . Prior studies aimed at defining rates of EBV infection by age across populations have used positivity for IgG antibodies targeting EBV proteins such as the viral capsid antigen (VCA) and EBV nuclear antigen 1 (EBNA1) [8] to classify individuals as EBV positive (ie, as ever exposed to EBV). IgG antibodies can also be used to better understand the nature of an individual's EBV infection. For example, a subset of long-term EBV carriers displays elevated levels of IgG antibody targeting the early antigen protein (EA) [9] . This EA complex is expressed as part of the EBV lytic cycle; therefore, elevated levels of EA indicate ongoing viral lytic activity (reactivation) and a potential lack of control over the virus [10] .
In contrast to IgG, immunoglobulin A (IgA) responses to viral exposure are believed to reflect recent reactivation at mucosal sites (eg, the oral epithelium) [11] . This type of immune response is of interest because of the oral route of EBV transmission. During primary infection, IgA responses against EBV in the oral cavity can be strong but are short lived [12] . The durability and spectrum of EBV-directed IgA responses in healthy adults are largely uncharacterized. However, it has been shown that individuals at greatest risk of developing NPC, an EBV-associated cancer, have elevated anti-EBV IgA responses to VCA and EBNA1 years before a cancer diagnosis [8, 13, 14] .
Although informative, prior studies of humoral responses to EBV infection [15, 16] have largely focused on measuring levels of IgG and IgA antibodies to a handful (<10) of the approximately 90 EBV protein targets [8] . With the advent of protein array systems capable of screening for antibody responses against the full complement of EBV proteins [17] [18] [19] , it is now feasible to evaluate humoral responses to EBV infection in a more comprehensive manner. Thus, we evaluated IgG and IgA anti-EBV antibody responses against 199 predicted sequences and 3 synthetic antigens from 86 EBV proteins involved in various stages of the EBV life cycle (eg, latent and lytic cycles) among 289 healthy individuals from Taiwan, a region with high rates of EBV-associated cancer.
METHODS
A total of 289 healthy, asymptomatic adults who served as controls for 2 previously published Taiwanese studies were selected for this report [20, 21] . Details are described in the Supplementary Materials. A previously described EBV protein microarray targeting IgG and IgA antibodies against 199 predicted EBV protein sequences (86 EBV proteins) from 5 EBV strains (AG876, Akata, B95-8, Mutu, and Raji) was used [17, 18, 22, 23] . Briefly, these 199 sequences represent nonredundant open reading frames from 5 EBV strains representing both African (Mutu, Raji, and AG876) and Asian (Akata) variants, as well as known splice variants identified in the literature. Eighty-five percent of 199 predicted sequences represented complete transcripts of EBV genes. The remaining 30 predicted sequences represented linear segments from 8 EBV genes >1000 bp long. Each of the protein sequences cloned into the pXT7 expression vector prior to printing onto the microarray included N-terminal 10x histidine (His) and C-terminal hemagglutinin (HA) tags to confirm expression on the microarray.
After printing, anti-polyHis probing confirmed the presence of 99.5% of sequences; anti-HA probes confirmed the presence of 98.5% of sequences. High coverage was achieved across the 5 EBV strains, with 97% of the predicted sequences from each strain represented on the microarray at ≥99% homology.
A positive antibody response in a healthy adult was defined as a response greater than that individual's person-specific background (mean of 4 no-DNA-control spots plus 1.5 standard deviations) [17] . As previously reported [23] , we included blinded quality control replicates during testing and observed good reproducibility for antibodies measured using this custom protein microarray. The average percentage agreement for classifying an individual's antibody response as positive versus negative was high for both IgA (84%; range, 52%-100%) and IgG (79%; range, 48%-100%), respectively. The antibody level (determined on the basis of the standardized signal intensity output from the array) was further grouped into quartiles (4 categories) based on the population distribution of the response for each given antibody.
Based on coefficients of variation reported from the previous study [ 
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Statistical Analysis
Visualization and statistical analyses were conducted using R statistical software. Details on the statistical analyses are described in the Supplementary Materials. Briefly, to pool data across the 2 study populations, we used population-specific cut points to generate similar underlying antibody distributions and then compared individual response rates (ie, percentage positivity values) across immunoglobulin class and EBV life cycle. We estimated the correlation between antibodies across immunoglobulin classes (ie, IgG against protein X versus IgA against protein X) and within each immunoglobulin class (ie, IgG against protein X versus IgG against protein Y), using Spearman correlation coefficients. All individuals were clustered according to the positive responses across the full EBV proteome, using unsupervised hierarchical clustering with binary distance and complete linkage [24] . To examine the association between environmental and genetic risk factors (ie, smoking, alcohol drinking, and HLA alleles) and biological groupings of antibody response (eg, responses directed against a select EBV life cycle), we used the sequence kernel association test-combined (SKAT-C) from the single-nucleotide polymorphism set [25] , using binary variables (with a positive antibody response assigned a value of 1 and a negative response assigned a value of 0). Subjects   100%  100%  100%  100%  100%  100%  100%  99%  99%  99%  98%  98%  98%  97%  97%  96%  96%  96%  94%  10%  9%  8%  8%  8%  8%  7%  7%  6%  6%  6%  6%  4%  4%  4%  4%  3%  2%  2%  1%   96%  94%  93%  93%  83%  80%  80%  79%  77%  70%  70%  65%  65%  65%  64%  64%  62%  61%  60%  55%  2%  2%  2%  2%  1%  1%  1%  1%  1%  1%  1%  0%  0%  0%  0%  0%  0%  0% Figure 1B and Supplementary Table 2 ). This contrasts with 33 EBV proteins that were weakly immunogenic for IgA ( Figure 1C ; Supplementary Table 2) .
RESULTS

Anti-EBV
Antibody Responses Against EBV Proteins Expressed at Different Stages of the EBV Life Cycle
Although IgG responses were more common than IgA responses, the biological function of the target protein was also an important determinant of the host antibody response (Table 1) . IgG against EBV glycoproteins (median IgG positivity frequency, 68.4%) was more frequently observed than IgG targeting proteins from other stages of the EBV life cycle. Robust IgG responses to EBV latent proteins and proteins involved in the switch from latent to lytic infection were also observed (median positivity frequencies, 51.7% and 45.5%, respectively). Responses to EBV proteins involved in immediate early lytic proteins (median positivity frequency, 36.4%) were less widespread but still frequent, evidence of broad, long-term exposure to proteins from all stages in the EBV life cycle among healthy adults. IgA antibody responses against EBV glycoproteins (median IgA positivity frequency, 42.1%; Table 1 ) was also more frequently observed than responses against proteins from other stages of the EBV life cycle. The median positivity frequencies observed for IgA antibodies across proteins from latent and lytic phases of the EBV life cycle were similar (range, 15.6%-17.2%; Table 1), with 1 notable exception: IgA antibody responses against EBV proteins involved in the switch from latency to lytic phases were particularly infrequent, with a median positivity frequency of 0% (0 of 12; range, 0%-75%). This is particularly interesting because IgA responses to some of these proteins have been shown to be predictive of the risk of the EBV-associated malignancy NPC [8] . While correlations tended to be higher within rather than across antibody class, interimmunoglobulin correlations (ie, IgG vs IgA correlations) were higher when considering the same protein target (median Spearman correlation, 0.226; 23.0% of correlations had a Bonferroni-corrected P value of < .05), rather than different EBV proteins (median Spearman correlation, 0.127 [range, −0.334-0.563]; 1.9% of the correlations had a Bonferroni-corrected P value of < .05). Similar patterns were observed across all EBV life cycle stages (Supplementary Table 3 and Supplementary Figures 11A-E) .
Clustering of Antibody Responses by Immunoglobulin Class
Consistent with the observation that IgG responses to EBV were more frequently observed than IgA responses, we noted that IgG responses to a particular antigenic target had, on average, a higher correlation with IgG responses to other antigenic targets, rather than with IgA responses against the same target (median Spearman correlation, 0.495
Clustering of Healthy, Asymptomatic Adults According to Anti-EBV
Antibody Responses
In addition to understanding the breadth of the antibody response marking EBV exposure in healthy adults, hierarchical clustering identified 4 distinct patterns among study participants that could be distinguished by their average number of ) displayed a high level of IgA reactivity, indicating that ongoing EBV exposure at mucosal surfaces is not an infrequent event in healthy, Taiwanese adults previously exposed to EBV. We further examined whether group 4 participants were more likely to respond to targets from a specific stage of the EBV life cycle and observed that these subjects had elevated responses to all stages ( Supplementary Figures 12A and B) . Notably, this high response pattern included higher IgA antibody reactivity against immediate early lytic proteins (median number of positivity among individuals in this group, 1; interquartile range, 0-2.5) compared to the other groups (median number of positivity, 0; interquartile range, 0-0; P = 1.9 × 10 -7 , by the rank test).
We further compared the antibody pattern in group 4 to that previously described among patients with NPC (n = 175) [23] .
IgG and IgA responses observed among individuals in group 4 were broadly comparable to those observed among NPC cases ( Figure 3B ). When we estimated a cancer risk score for asymptomatic individuals in our study by using our previously reported 14-antibody NPC risk stratification signature [23] , 79% of individuals in group 4 had scores that ranked in the highest quartile of cancer risk, compared with only 7% of individuals in groups 1-3 (P = 2.2 × 10 -14 , by the χ 2 test; Table 2 ). These findings suggest that healthy individuals can be classified as having distinct patterns of EBV responses and that a proportion of healthy individuals are characterized by high IgG and IgA responses typically observed among individuals at highest risk of NPC development.
Smoking Is Associated With Differential EBV-Directed IgA Antibody
Responses
The extent to which the effect of known NPC risk factors is mediated through their ability to modulate immune responses to EBV is not fully understood. We observed that individuals from group 4 also had the highest proportion of current smokers, compared with other groups (72% vs 45%; P = 0.02, by the χ 2 test). In addition, when considering the proteome-wide antibody response, the total level of the IgA response but not the IgG response was significantly different between smokers and nonsmokers in our population (P = .002, by the SKAT-C; Further, in logistic regression models that evaluated the association between smoking and each marker individually, we observed suggestive associations (P < .05) for multiple anti-EBV IgA antibodies from all stages of the EBV life cycle (37.9% [22 of 58] were associated with latent proteins, 8.3% [1 of 12] were associated with immediate early proteins, 20.0% [9 of 45] were associated with early lytic proteins, 6.4% [3 of 47] were associated with late lytic proteins, and 21.0% [4 of 19] were associated with glycoproteins; Supplementary Tables 4-8) . The strongest individual association was observed between smoking and IgA targeting LMP1(odds ratio, 4.64; P = .001; Figure 4B ), an EBV oncoprotein expressed in NPC tumors that is normally considered a weakly immunogenic protein [26, 27] . Taken together, these findings suggest that smoking may alter the anti-EBV mucosal antibody response.
We also evaluated the association between anti-EBV antibody responses, alcohol drinking, and HLA alleles that modulate However, no statistically significant associations persisted after correction for multiple comparisons.
DISCUSSION
Our findings represent the first comprehensive evaluation of natural variation in the host antibody response to the full spectrum of EBV proteins. This unique characterization was made possible through the use of protein microarray technology in a population of healthy, asymptomatic adults from Taiwan. Because the antibody repertoire can shed light on exposure to viral proteins, this virus-wide description of host response to the EBV proteome represents an important step forward in understanding population-level variation that might have implications for multiple EBV-related diseases. We found that all adults evaluated in our study had evidence of exposure to EBV proteins, that these EBV-positive adults were more likely to mount IgG rather than IgA antibody responses to EBV, and that responses against glycoproteins were particularly prevalent. If the IgG response targeting 1 EBV protein (eg, protein X) was elevated in an individual, they were more likely to mount an IgG response targeting other antigens, rather than an IgA response against protein X, likely reflecting differential timing of exposure (longer-term exposure for IgG and more-recent exposure for IgA) and separate triggering mechanisms in different compartments (eg, oral mucosa vs systemic circulation). Approximately one quarter of the subjects in this study displayed antibody response patterns similar to NPC cases, including positive responses reflecting exposure to immediate early antigenic targets, such as Zta and Rta. Importantly, our data indicate that smoking is associated with altered IgA antibody patterns that could reflect poor control over EBV lytic activity, suggesting a possible mechanism to explain the role of smoking in the etiology of NPC.
Previous studies have evaluated responses against a handful of anti-EBV antibodies by using techniques including immunoblot and microarray chips targeting 10-15 EBV proteins [28, 29] . Zheng et al used a microarray to test 82 EBV open-reading frames in a study that included 10 nondiseased adults and showed that these adults mounted IgG responses against an average of 17 proteins (at 1:100 serum dilution) and IgA antibodies against an average of 13 proteins (at 1:1000 serum dilution) [19] . This is in line with our findings of more frequent IgG reactivity, rather than IgA reactivity. In the present study, we expanded testing to 199 EBV open-reading frames among 289 asymptomatic adults. Because our array was not designed to detect antibodies to conformational epitopes that require glycosylation, future studies will be required to better understand patterns of response to those epitopes and how they are related to those reported herein.
Our finding that antibody responses to some glycoproteins were the most prevalent is biologically plausible because these proteins are expressed on the viral surface and therefore readily accessible as targets for the immune system [30, 31] . Given that IgA responses are thought to reflect recent pathogen exposure, our finding that IgA responses to glycoproteins were also more frequently observed than responses against proteins from other stages of the EBV life cycle suggests that the presence of EBV in the oral cavity is not a rare event [32] . It was notable that individuals in groups 2 and 4 (39% [114]) mounted a substantial, proteome-wide IgA response. This supports data from studies reporting EBV viral load shedding in the saliva of the majority of healthy adults measured [32, 33] , as well as EBV reactivation rates that are much more frequent than those for other herpesviruses, such as cytomegalovirus [34] . An important public health implication of our data is that smoking, a modifiable behavior, was associated with elevated IgA responses against EBV. An association between smoking and EBV reactivation has been posited by one study, which evaluated VCA/IgA in individuals from southern China [35] . In the present study, we expand beyond VCA/IgA alone to demonstrate large-scale differences in the EBV-directed IgA repertoire in smokers. The most significant smoking association was observed for IgA responses against LMP1, an important NPC oncogene that has cell-transforming ability in rodent fibroblasts [36] . In addition to these individual antibody associations, we observed that individuals in group 4 also had the highest proportion of current smokers. Taken together, these findings suggest that smoking may negatively impacts an individual's ability to control EBV infection, leading to an increased frequency of viral reactivation/exposure in the host. However, we did not assess the degree to which the established association between smoking and NPC is mediated by interindividual variation in the immune response to this ubiquitous virus. The underlying biological mechanisms merit further investigation.
In conclusion, we described the pattern of the IgG and IgA responses to EBV among asymptomatic, healthy adults, using a protein microarray chip targeting 199 EBV protein sequences. Given that the generation of antibodies is a complex process requiring interplay between viral antigens and numerous compartments of the immune system [37] , our study represents an initial but important step in understanding the immune response to EBV infection. In the future, our approach could be applied to other populations to characterize the similarities and differences observed in the humoral response to EBV in individuals predisposed to different EBV-associated conditions (eg, sub-Saharan Africans at higher risk of Burkitt lymphoma). Such studies could elucidate subsets of EBV-infected individuals at highest risk of EBV-associated clinical conditions and help identify targets for the development of effective immunodiagnostics.
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